The information presented on this website, including but not limited to any forward-looking statements, forecasts, or business projections, is for informational purposes only and are based upon various assumptions, and these assumptions may prove to be incorrect. These forward-looking statements, forecasts, and business projections are based on current expectations and assumptions which may change over time due to various market factors, economic conditions, and business decisions. Actual results may differ materially from those expressed or implied in any projections or forecasts. They should not be construed as financial or investment advice. We make no guarantees regarding the performance or outcomes described and do not assume nor accept any responsibility for the accuracy or completeness of these statements and we do not accept liability for any loss or damages that may arise from reliance on this information. You are encouraged to perform your own due diligence and consult with a qualified financial advisor before making any business or investment decisions.
*The testimonials provided through this website are given by investors who have invested cash into Endless Corporation in exchange for securities of the company, and they are offering such testimonials in their individual capacity. Such persons have not received and will not receive in the future compensation for providing such testimonials.
Reg A
**In no way limiting the foregoing, any reference to any objective, goal, intention, or plan of Endless Corporation becoming, emulating, or operating in a similar manner as Fortune 100 and 500 companies is not a guarantee that it will be able to do so, or will not elect to do otherwise, now or in the future. In addition, while this website may reference aspirations of Endless Corporation for a future public listing, it is still formulating and has not yet decided on or yet implemented a plan to achieve such result. Future results are not guaranteed, nor is how, the capability to achieve such results, and no investment decision should be based upon the potential of a future public listing, or any other potential future event discussed herein.
These offering materials may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company's management. When used in the offering materials, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. These statements reflect management's current views with respect to future events and are subject to risks and uncertainties that could cause the company's actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.
Please note investors in this offering will be clients of the issuer and not Dalmore Group, LLC ("Dalmore"), a registered broker-dealer and member FINRA/SIPC. Dalmore's role in the transaction is to facilitate back-office and regulatory functions related to the Regulation A transaction, and acts only as the broker/dealer of record for the offering listed. Dalmore is not providing investment advice or recommendations, or legal or tax advice.
This Reg A investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. All investors should make their own determination, with the assistance of their own financial or other advisors, as to whether or not to make any investment, based on their own independent evaluation, analysis, and circumstances.
No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement filed by the company with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification. An indication of interest involves no obligation or commitment of any kind. An offering statement regarding this offering has been filed with the SEC. You may obtain a copy of the preliminary offering circular that is part of that offering statement. Form 1-A Filing with SEC
Genetic Remediation
Advanced meristem tip culture and thermotherapy protocols to eliminate viruses from infected mother stock and restore clean genetics.
0
remediation success rate
Genetic Remediation
Advanced meristem tip culture and thermotherapy protocols to eliminate viruses from infected mother stock and restore clean genetics.
0
remediation success rate
Your highest-value genetics don't have to die. Thermotherapy plus meristem culture. Triple-verified clean. Ninety-five percent success rate.
The Remediation Journey
HLVd+
Stunted growth, reduced yields, brittle stems. Systemic viroid infection threatens your entire facility.
Verified
Full vigor restored. Triple-verified pathogen-free across three consecutive PCR panels.
HLVd+
Stunted growth, reduced yields, brittle stems. Systemic viroid infection threatens your entire facility.
0%
Success Rate
Verified
Full vigor restored. Triple-verified pathogen-free across three consecutive PCR panels.
The Protocol
Your infected plants are received in our quarantine facility. We run full diagnostics to identify all pathogens present and determine the optimal remediation protocol.
Plants undergo controlled heat exposure (38°C for 4–8 weeks) that disrupts viral replication in actively growing tissue while keeping the plant alive.
While the virus is suppressed, we excise the smallest possible meristem tip (0.1–0.3mm), where the virus concentration is lowest, under sterile conditions.
Excised meristems are cultured and tested at multiple stages. Only plants that test negative across all pathogen panels on three consecutive tests are cleared.
Verified clean clones are multiplied and delivered to you. We retain a cryo backup so your remediated genetics are permanently preserved.
The full process, from intake through clean stock delivery, typically takes 6–9 months. Thermotherapy alone requires 4–8 weeks, followed by culture establishment and triple verification.
If our first protocol doesn't achieve clean status, we attempt alternative approaches (different thermotherapy parameters, chemotherapy). If all attempts fail, you are charged only for diagnostics, not the full remediation fee.
Our protocols are validated for a wide range of plant species. Contact us with your specific cultivar and pathogen information, and we'll assess feasibility before you commit.
Get in Touch
Whether you're scaling up or starting out, our team is ready to help you grow with clean, consistent genetics.
